Skip to main content
OpenTrials
Completed

NCT Number: NCT03844022

MRI in McArdle Disease (GSDV)

The aim of this study is to describe the degree of muscle wasting in patients with McArdle disease judged by MRI, quantitative magnetic resonance (DIXON) and T1 weighted images, and muscle strength, collected across multiple European sites and compared to healthy controls.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Copenhagen Neuromuscular Center, Rigshospitalet

Copenhagen, Denmark

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • GSDV or healthy controls

Exclusion criteria

  • MRI contradictions

Treatment and study plan

MRI

Diagnostic Test

magnetic resonance imaging

Primary outcomes

  1. DIXON MRI

    Time frame: 1 time

    Whole body quantitative muscle fat fraction analyses (DIXON)

Secondary outcomes

  1. Muscle strength

    Time frame: 1 time

    MRC scale

  2. T1 MRI

    Time frame: 1 time

    Whole body qualitative muscle fat fraction analyses (T1)

  3. Back pain questionnaire

    Time frame: 1 time

    Back pain questionnaire

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Registry information

Official study title

MRI in McArdle Disease (Glycogen Storage Disease Type V)

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Feb 18, 2019
Registry last updated
Feb 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.